Fennec pre-announces Q4 2023 net revenue ~$9.2-9.7M, up 41-49% QoQ

FENNEC PHARMACEUTICALS INC.

Q4 2023 net revenue expected $9.2-9.7M, a 41-49% increase vs Q3 2023.
Full-year 2023 net revenue expected ~$20.7-21.2M.
Audited full-year results expected on or about March 26, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FENNEC PHARMACEUTICALS INC. reported Fourth quarter 2023 results: revenue approximately $9.2 to $9.7 million.

Period: Fourth quarter 2023
Revenue: approximately $9.2 to $9.7 million
Result: preliminary results

Exact text from the filing

• Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FENNEC PHARMACEUTICALS INC. reported Full-year 2023 results: revenue approximately $20.7 to $21.2 million.

Period: Full-year 2023
Revenue: approximately $20.7 to $21.2 million
Result: preliminary results

Exact text from the filing

• Full-year 2023 net revenues are expected to be approximately $20.7 to $21.2 million.

View on SEC.gov

493 earnings releases filed in the last 30 days. Browse all earnings releases →

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-031470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.